Cadonilimab + lenvatinib for endometrial neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 21 Apr 2023: Trial registered, NCT05824481
  2. 8 May 2023: Trial started, NCT05824481

The trials

NCT05824481: Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

State
Under way
Phase
Phase 2
People
32 planned
Started
8 May 2023
Primary completion
31 Jul 2025
Arms
Cadonilimab + Lenvatinib
Results
None posted
  1. 21 Apr 2023: Trial registered
  2. 8 May 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.